Nature Medicine Study Identifies 2 Daraxonrasib Escape Routes in Pancreatic Cancer
Updated
Updated · Oncodaily · Aug 16
Nature Medicine Study Identifies 2 Daraxonrasib Escape Routes in Pancreatic Cancer
3 articles · Updated · Oncodaily · Aug 16
Summary
Circulating tumor DNA from daraxonrasib Phase 1/2 patients showed pancreatic tumors mainly resisted through KRAS amplification or by activating backup growth pathways, rather than mutating the drug’s binding site.
Human and mouse models then linked those escape routes to rational combination strategies, with daraxonrasib paired with DNA-damage-response drugs, growth-factor-receptor therapies or another RAS inhibitor such as zoldonrasib blunting resistance in the lab.
The findings follow ASCO 2026 trial results that had highlighted daraxonrasib as a promising option in a cancer with few effective treatments, shifting attention to how long responses can be sustained.
The study suggests earlier mapping of resistance could help design combination regimens that prolong benefit in pancreatic cancer, where single-agent targeted therapies often lose effectiveness.